renal cell carcinoma Archives - Kidney Cancer Support Network

ASCO GU 2021: Outcomes of first-line immunotherapy combinations in metastatic kidney cancer

Combinations of immunotherapy drugs nivolumab plus ipilimumab and immunotherapy/vascular endothelial growth factor (VEGF) inhibitors are widely used for the treatment of metastatic renal cell carcinoma (RCC). However, limited information is available to compare the outcomes from different combinations. At the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) over the weekend, data […]

Feb 15, 2021 / Comments Off / Sharon Kell / Tags: ASCO, combination therapy, immunotherapy, overall survival, renal cell carcinoma, response rate, VEGF inhibitors

ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

Results from the phase 3 CLEAR study, presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium over the weekend, showed that lenvatinib used in combination with either pembrolizumab or everolimus resulted in improved survival and tumour shrinkage compared to sunitinib when used as a first-line treatment for patients with advanced renal cell […]

Feb 15, 2021 / Comments Off / Sharon Kell / Tags: Afinitor, ASCO, combination therapy, everolimus, first-line treatment, Keytruda, lenvatinib, Lenvima, overall survival, pembrolizumab, progression-free survival, renal cell carcinoma

ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

A gene called MET codes for a protein called MET tyrosine protein kinase (also called hepatocyte growth factor receptor), which stimulates the growth and development of tumours. MET tyrosine protein kinase is a key driver of the growth and development of papillary renal cell carcinoma (pRCC). In this study presented at the American Society of […]

Feb 15, 2021 / Comments Off / Sharon Kell / Tags: ASCO, c-Met inhibitor, Cabometyx, cabozantinib, crizotinib, MET, papillary RCC, progression-free survival, renal cell carcinoma, savolitinib

ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer

In a small phase 2 study presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), the novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), showed promising anti-cancer activity in combination with cabozantinib in patients with metastatic clear cell renal cell carcinoma (RCC) that had been previously treated. Kidney cancers develop […]

Feb 12, 2021 / Comments Off / Sharon Kell / Tags: ASCO, belzutifan, Cabometyx, cabozantinib, HIF-2α, MK-6482, overall survival, progression-free survival, renal cell carcinoma, safety and tolerability, side effects

ASCO GU 2021: Immunotherapy for untreated non-clear cell kidney cancer

Results of a retrospective study presented during the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) looked at the effect of immune checkpoint inhibitors (immunotherapy, e.g. nivolumab, ipilimumab, pembrolizumab) on the survival of patients with metastatic non-clear cell renal cell carcinoma (RCC) compared to targeted therapy with vascular endothelial growth factor (VEGF) […]

Feb 12, 2021 / Comments Off / Sharon Kell / Tags: ASCO, checkpoint inhibitors, immunotherapy, mTOR inhibitors, non-clear cell kidney cancer, overall survival, progression-free survival, renal cell carcinoma, response rate, VEGF inhibitors

ASCO GU 2021: Long-term follow-up of kidney cancer patients on nivolumab plus ipilimumab combination

Long-term follow-up data from the CheckMate-214 study of the nivolumab plus ipilimumab combination in untreated, advanced clear cell kidney cancer patients were presented at the virtual American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco this weekend. Patients were followed for at least 4 years after treatment with nivolumab plus ipilimumab […]

Feb 12, 2021 / Comments Off / Sharon Kell / Tags: ASCO, clear cell RCC, combination therapy, immunotherapy, ipilimumab, nivolumab, Opdivo, progression, renal cell carcinoma, Yervoy

ASCO GU 2021: Nivolumab plus ipilimumab combination in patients with non-clear cell kidney cancer

Data from the CheckMate-920 study on the safety and effectiveness of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) was presented at the virtual American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco this weekend. CheckMate-920 is a community-based, phase IIIb/IV clinical trial of nivolumab plus […]

Feb 12, 2021 / Comments Off / Sharon Kell / Tags: ASCO, combination therapy, immunotherapy, ipilimumab, nivolumab, non-clear cell kidney cancer, Opdivo, renal cell carcinoma, Yervoy

Patterns of metastases for clear cell, papillary and chromophobe RCC associated with survival

A recent study published in JAMA Network Open looked at the data from over 10,000 renal cell carcinoma (RCC) patients from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and reported on the sites of metastases for three of the RCC subtypes and their survival outcomes. Metastases from clear cell RCC (9252 patients, 92%) […]

Feb 10, 2021 / Comments Off / Sharon Kell / Tags: cancer outcomes, chromophobe RCC, clear cell RCC, metastases, papillary RCC, prognosis, renal cell carcinoma

ASCO GU 2021: Cabozantinib for the treatment of kidney cancer brain metastases

Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are prevented from getting to the brain by a membrane called the blood-brain barrier. In this study, the results of which will be presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) […]

Feb 09, 2021 / Comments Off / Sharon Kell / Tags: ASCO, brain metastases, Cabometyx, cabozantinib, metas, overall survival, renal cell carcinoma, response rate, treatments response

ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer

The past couple of years has seen a number of combination therapies for the first-line treatment of advanced/metastatic renal cell carcinoma (RCC) become available. At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco this week, ongoing results from the phase 3 CheckMate-9ER clinical trial with the nivolumab plus cabozantinib […]

Feb 09, 2021 / Comments Off / Sharon Kell / Tags: ASCO, Cabometyx, cabozantinib, combination therapy, immunotherapy, nivolumab, Opdivo, overall survival, progression-free survival, renal cell carcinoma, response rate, targeted therapy, treatments response, VEGF inhibitors

Showing 1 to 10 of 745 results

TOP

Settings

Shopping Bag